Publications by authors named "Mark J Gnoth"

Claim this Profile
T
The use of surrogate matrices in bioanalytical preclinical safety testing using chromatographic methods: a recommendation from the European Bioanalysis forum.
Lee Goodwin, Stuart McDougall, Mark Jean Gnoth, Daniel Mascher, Luca Ferrari

Bioanalysis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspective on LC-MS(/MS) for biotherapeutic and biomarker proteins in research and regulated Bioanalysis: a consolidation of more than a decade of experience across the European Bioanalysis Forum community (Part 2: "The How").
Nico van de Merbel, Mark Jean Gnoth, Amanda Wilson, Peter Blattmann, Benno Ingelse

Bioanalysis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspective on LC-MS(/MS) for biotherapeutic and biomarker proteins in research and regulated Bioanalysis: a consolidation of more than a decade of experience across the European Bioanalysis Forum community (Part 1: "The What").
Amanda Wilson, Mark Jean Gnoth, Nico van de Merbel, Peter Blattmann, Benno Ingelse

Bioanalysis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations and feedback from the European Bioanalysis Forum Workshop: 1 year into ICH M10 - keeping our finger on the pulse.
Philip Timmerman, Matthew Barfield, Enric Bertran Portabella, Salvatore Calogero, Kyra Cowan, Mark Jean Gnoth

Bioanalysis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunocapture LC-MS(/MS) assays for biotherapeutic and biomarker proteins: the European Bioanalysis Forum continuing discussions on scientific and regulatory challenges.
Matthew Barfield, Michael Blackburn, Peter Blattmann, Benno Ingelse, Gregor Jordan, Mark J Gnoth

Bioanalysis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transporter tandems: precise tools for normalizing active transporter in the plasma membrane.
Julia Tschirka, Markus Bach, Ilmars Kisis, Julia Lemmen, Mark Jean Gnoth

Biochem J· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bypassing nonparallelism of a monoclonal antibody ligand-binding assay by employment of alternative assay formats.
Stefan Kiesgen, Armin Schröder, Thomas Schwarz, Oliver Czupalla, Manuela Braun, Mark Jean Gnoth

Bioanalysis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.
Brandon Swift, Noelia Nebot, Jin Kyung Lee, Tianxiang Han, William R Proctor, Mark J Gnoth

Drug Metab Dispos· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.
Reiner Frey, Christian Scheerans, Martin Blunck, Wolfgang Mück, Mark Jean Gnoth

J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.
Uwe Muenster, Christian Pelzetter, Thomas Backensfeld, Andreas Ohm, Thomas Kuhlmann, Mark Jean Gnoth

Eur J Pharm Biopharm· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.
Mark Jean Gnoth, Ulf Buetehorn, Uwe Muenster, Thomas Schwarz, Steffen Sandmann

J Pharmacol Exp Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
Frank Wunder, Mark Jean Gnoth, Andreas Geerts, Daniel Barufe

Mol Pharm· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Hartmut Schirok, Raimund Kast, Santiago Figueroa-Pérez, Samir Bennabi, Mark J Gnoth

ChemMedChem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Uwe Muenster, Birgit Grieshop, Karsten Ickenroth, Mark Jean Gnoth

Pharm Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Oleg V Evgenov, Daniel S Kohane, Kenneth D Bloch, Johannes-Peter Stasch, Gian P Volpato, Mark J Gnoth

Am J Respir Crit Care Med· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
Rio Dumitrascu, Norbert Weissmann, Hossein Ardeschir Ghofrani, Eva Dony, Knut Beuerlein, Mark Jean Gnoth

Circulation· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Oleg V Evgenov, Fumito Ichinose, Natalia V Evgenov, Mark J Gnoth, George E Falkowski

Circulation· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis